Welcure Drugs & Pharmaceuticals Limited (524661) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Welcure Drugs & Pharmaceuticals Limited ₹0.19, price ₹0.21, upside -11.5%, quality 35 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Welcure Drugs & Pharmaceuticals Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹0.1582 – ₹1.44 · fair‑value band ₹0.1136 – ₹0.3316 · the ₹0.2100 price screens above the ₹0.1858 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Welcure Drugs & Pharmaceuticals in your weekly email
Every Wednesday you see whether Welcure Drugs & Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Welcure Drugs & Pharmaceuticals Limited engages in the wholesale of pharmaceutical and medical goods in India. The company was incorporated in 1996 and is based in Delhi, India.
Stock analysis
Welcure Drugs & Pharmaceuticals Limited (524661) currently trades at ₹0.2100, while our model-based Fair Value estimate is ₹0.1858, 11.5% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 6 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: ₹0.1136 (bear) to ₹0.3316 (bull), the price of ₹0.2100 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 35/100 (below-average quality), in the Health Care sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Welcure Drugs & Pharmaceuticals Limited reported revenue of ₹3.7B in FY2026 versus ₹1.1M in FY2022, a compound +668.1%/yr. Reported net income was −₹54.9M in FY2026.
Key figures
Market cap ₹27.6M (≈ $286K) · P/E ratio 643.3 · P/S ratio 30.2 · EPS (TTM) ₹0.0020 · Net margin −1.5% · Return on equity 5.7% · Return on assets (EBIT) −0.9% · Operating margin 1.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 73% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Health Care peers we cover trades at −40% fair-value upside, at −12%, 524661 screens cheaper than that median.
Fair Value models
Bear ₹0.1136Fair Value ₹0.1858Bull ₹0.3316
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.0010 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.66/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1,389.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+387.1%
Start year 2021 (pandemic). Over 10 years: +127.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+110.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
41.2% (2021) → −1.9% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−18.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about −21.9% a year for the price.
Compare Welcure Drugs & Pharmaceuticals Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 51 stocks
Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score35 · Bottom 25%
Fair Value upside+19.0% · Above median
Profitability
Return on equity (TTM)5.7% · Above median
Return on assets1.6% · Below median
Net margin (TTM)2.1% · Below median
Operating margin (TTM)1.1% · Below median
Growth and dividend
Revenue growth1.0% · Below median
Dividend yield (TTM)0.0% · Bottom 25%
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Welcure Drugs & Pharmaceuticals Limited (524661) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹0.1858 versus a price of ₹0.2100, about −12% upside (overvalued).
What is the fair value of 524661?
Our model-based fair value for Welcure Drugs & Pharmaceuticals Limited is ₹0.1858 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹0.2100.
What is the quality score of 524661?
Welcure Drugs & Pharmaceuticals Limited has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Welcure Drugs & Pharmaceuticals Limited (524661)?
Our model-based price target is the fair value of ₹0.1858 (as of Sep 24, 2026) from 6 valuation models. Cautious scenario ₹0.1136, optimistic scenario ₹0.3316. It is a calculation from audited fundamentals, not an analyst target.
What is the Welcure Drugs & Pharmaceuticals Limited stock forecast for 2026?
Our models put fair value at ₹0.1858, about −12% upside versus a price of ₹0.2100 (overvalued). Cautious scenario ₹0.1136, optimistic scenario ₹0.3316. The calculation is refreshed regularly with new filings.
What growth is priced into Welcure Drugs & Pharmaceuticals Limited (524661)?
For today's price to be fair in a discounted-cash-flow model, Welcure Drugs & Pharmaceuticals Limited would have to grow free cash flow by -18.7 % per year for five years (discount rate 11.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +387.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 524661 use?
Our models discount Welcure Drugs & Pharmaceuticals Limited at 11.5 %: a base by market capitalisation (nano), damped by beta 0.71, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Welcure Drugs & Pharmaceuticals Limited that is -18.7 % per year a year over ten years, using the same discount rate (11.5 %) and the same formula as our fair value.
How much growth has Welcure Drugs & Pharmaceuticals Limited (524661) delivered so far?
Over the past 5 years revenue at Welcure Drugs & Pharmaceuticals Limited grew +387.1 % a year. The price currently implies -18.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Welcure Drugs & Pharmaceuticals Limited (524661) growing?
The median revenue growth in the sector is +8.1 % a year. That is the yardstick for the growth priced into Welcure Drugs & Pharmaceuticals Limited (-18.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Welcure Drugs & Pharmaceuticals Limited (524661)?
The free-cash-flow yield on the price is 6.69 %: that much free cash flow Welcure Drugs & Pharmaceuticals Limited produces per unit of market value. When it exceeds the discount rate of our models (11.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Welcure Drugs & Pharmaceuticals Limited (524661)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Welcure Drugs & Pharmaceuticals Limited it is ₹0.1858 per share (as of Sep 24, 2026), against a price of ₹0.2100. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is Welcure Drugs & Pharmaceuticals Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 524661 trades above its calculated fair value: price ₹0.2100, fair value ₹0.1858, a gap of about −12% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 524661?
No. The price is what the market pays today (₹0.2100); the fair value is what the company's own numbers justify (₹0.1858). For Welcure Drugs & Pharmaceuticals Limited the two are ₹0.0242 per share apart. That gap is exactly why we show both numbers side by side.
How much is Welcure Drugs & Pharmaceuticals Limited worth?
The market values Welcure Drugs & Pharmaceuticals Limited at about ₹27.6M (market capitalisation, as of Sep 24, 2026). Per share that is ₹0.2100; our models calculate a fair value of ₹0.1858 per share.
What do the bullish and bearish scenarios say about 524661?
Our models span a range for Welcure Drugs & Pharmaceuticals Limited: cautious scenario ₹0.1136, base ₹0.1858, optimistic ₹0.3316 per share (as of Sep 24, 2026, price ₹0.2100). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Welcure Drugs & Pharmaceuticals Limited (524661)?
Balance-sheet figures for Welcure Drugs & Pharmaceuticals Limited (as of Sep 24, 2026): return on equity 5.7%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is 524661 from its 52-week high?
Welcure Drugs & Pharmaceuticals Limited trades at ₹0.2100, about 73% below its 52-week high of ₹0.7700 and 5% above the low of ₹0.2000 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹0.1858 is for.
Which stocks are comparable to Welcure Drugs & Pharmaceuticals Limited?
From the same area (Health Care) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Welcure Drugs & Pharmaceuticals Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹0.2100, calculated fair value ₹0.1858 (−12%), Quality Score 35/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 524661 calculated?
We run Welcure Drugs & Pharmaceuticals Limited through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹0.1858, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Welcure Drugs & Pharmaceuticals Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Welcure Drugs & Pharmaceuticals Limited (524661)?
The closing price on Oct 1, 2026 was ₹0.2100. Our model-based fair value is ₹0.1858, about −12% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Welcure Drugs & Pharmaceuticals Limited right now?
The model range is unusually wide (₹0.1136 to ₹0.3316). The outcome hinges heavily on assumptions, so read the point estimate with caution. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Welcure Drugs & Pharmaceuticals Limited
How large is the market capitalisation of Welcure Drugs & Pharmaceuticals Limited (524661)?
The market capitalisation of Welcure Drugs & Pharmaceuticals Limited is ₹27.6M (≈ $286K). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Welcure Drugs & Pharmaceuticals Limited (524661)?
The price-to-earnings ratio of Welcure Drugs & Pharmaceuticals Limited is 643.3 (as of Sep 24, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Welcure Drugs & Pharmaceuticals Limited (524661)?
The price-to-sales ratio of Welcure Drugs & Pharmaceuticals Limited is 30.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Welcure Drugs & Pharmaceuticals Limited (524661)?
Earnings per share at Welcure Drugs & Pharmaceuticals Limited are ₹0.0020 (price ÷ EPS = P/E 643.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Welcure Drugs & Pharmaceuticals Limited (524661)?
The net margin of Welcure Drugs & Pharmaceuticals Limited is −1.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Welcure Drugs & Pharmaceuticals Limited (524661)?
The return on equity (ROE) of Welcure Drugs & Pharmaceuticals Limited is 5.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Welcure Drugs & Pharmaceuticals Limited (524661)?
On an EBIT basis the return on assets of Welcure Drugs & Pharmaceuticals Limited is −0.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Welcure Drugs & Pharmaceuticals Limited (524661)?
The operating margin of Welcure Drugs & Pharmaceuticals Limited is 1.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Welcure Drugs & Pharmaceuticals Limited (524661)?
Revenue at Welcure Drugs & Pharmaceuticals Limited is growing +1.0% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed
Watch Welcure Drugs & Pharmaceuticals Limited in the live analysis
One click puts Welcure Drugs & Pharmaceuticals Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
